Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared to the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC).

Study close to accrual
Breast Cancer
DRUG: Carboplatin|DRUG: Everolimus
Progress-free survival (PFS), The time from the date of randomization to confirmed disease progression or death from any cause, whichever occurs first., up to 3 years
Overall Response Rate (ORR), Overall Response by RECIST 1.1. the best response recorded from the start of the study treatment until the end of treatment., up to 3 years|Overall Survival, The time from the date of randomization to death from any cause., up to 3 years|Clinical Benefit Rate, The best overall response rate including complete response (CR) + partial response (PR) + stable disease (SD) \>= 6 months., up to 3 years
The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared to the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC).

Study close to accrual